[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-female-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-female-adults":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100654480","phase-1-a-study-of-navlimetostat-bms-986504-drug-interactions-and-food-effect-in-healthy-participants-100654480",false,"NCT07800897","A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants","A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants","Inclusion Criteria\n\n* Participants must be healthy adult female (as assigned at birth) individuals not of childbearing potential (INOCBP) who have no clinically significant findings on medical history, physical examination (PE), vital signs (VS), 12-lead electrocardiograms (ECGs), or clinical laboratory determinations, as assessed by the investigator.\n* Participants must have a BMI of 18.0 to 35.0 kg\u002Fm2, inclusive.\n\nExclusion Criteria\n\n* Participants must not have any significant acute or chronic medical illness (in the assessment of the investigator).\n* Participants must not have a history of prolonged bleeding or excessive bruising.\n* Participants must not have any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"FEMALE","18 Years","55 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants",[28],"Healthy Female Adults",[30,31,32,33,34,35,36,37,38],"PRMT5","MTAP","MRTX1719","MountainTAP","Healthy Adult Female","Individuals not of childbearing potential","Open Label Study","Clinical Research Unit","Phase 1","RECRUITING","2026-09-30",{"date":42,"type":43},"2026-10-05","ACTUAL",{"date":45,"type":43},"2026-08-31",{"date":47,"type":22},"2027-03-25",{"name":49,"class":50},"Bristol-Myers Squibb","INDUSTRY"]